<SEC-DOCUMENT>0000000000-25-004254.txt : 20250819
<SEC-HEADER>0000000000-25-004254.hdr.sgml : 20250819
<ACCEPTANCE-DATETIME>20250422163605
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-25-004254
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250422

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRESCENT BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		UPLOAD
		SEC FILE NUMBER:	333-285035

	BUSINESS ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-430-5595

	MAIL ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLYCOMIMETICS INC
		DATE OF NAME CHANGE:	20030711
PUBLIC REFERENCE ACCESSION NUMBER:		0001104659-25-014838
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
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M$++$%NDB"X02+>I&2&Z%DK 7=@L:38N%!:O@WMV%7[G>"SF#EFLKBJ[FNCY
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M4Z6>+3HA=G1U2^R2-9R47AMKNJ9 KUTLG^^QW6>=X3+MHK=[J8^RZ[6++8[
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MZQ-R^*KQ9+BGY\\)0?**<PM52^!)5YS4+I:1]87:A8C<BNHS@J,$XTYULLO
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MR>[H8I_MG,^4."[UTSFTJH_F]''PP6$+,48<+$1$1$1$1.1?!S=#/F-%AF$
MQEWOA^16Z2C!1CP--VH7J!\UO6F&B:AI,AKQ-A-R[8Y^(AA^9PV[8YQ,/J0@
MD!87U?JBFF$,/]</=\?,IYQOHYEP+()(UU@<U18.H\&@$2[N2HA.+ #S!'G3
ML6:"N#^&*EV.659KG6DNDK9_F%[@:'/A;2$B(B(B(B+RUX 1!9\S7-)]R?3-
M,AS#!@)3Y*O_+?7W2_BT:L"G#P<]M(OJ%/E^B+I,2W ,20<69)#>N.+N<_Z1
M:NV0GU, 62N\7P]A1-0.C$9H/U%#&W=[G#6R>55:V1VSK^)^4LU(&L^=Y/T8
M?1KMHH;@6VLDMGEZ%XJ(B(B(B,C/ &T!Q0#M@OA16"  ,@7K=$0&7O1O<=C$
MY8'U?J,VX(4!.#LTT9NK1H$+">&D=D=GC=W1ZV17$AU2.<E,=T>KAES7IY92
M"^>'7X<(HK61Z1N"?H*64N..-L&3:Z3Z7EC H*5&[,QB:_%#,IXVKJP$/N7L
M./<,"97GB+_/=ML8$1$1$1$1D;\9EL;ICT"$S)HSBY!KN)/$OZS36;F?U"YR
M<8V80)QDO!MV1X\,CIY.(G6Y331CHD80Y"K#7:9$0)S,]!;)%%&$@YAH%V3K
MX'--#IL%,B('!\+\ X4D,Z3$49KH6"G1]/E*:FU5S=A-8W72GE1(UB(3$IR$
M>*3+T;5D>RX8$1$1$1$1D;\6](IT+F!%GWF:=L7E(9?YR]$BXF0<8Q;XF7VI
MNDY4DP,L.N*X6&BP;RH/Z3211@7H%4@'J2$@DJ3R<%*[B//*ST/M IV!C%$X
MB<17-=]]GYD1_Y>AQ47V0^_J$N4G?<A5R"0FF<3VUS$A&F&BN19$,E^.VL7U
M4<=%1$1$1$1$_CCX=.0RG*7W9 &.RL$"_V2:5(PZ:JKKQL$!DPRB9Z1A!C8>
M&8*2Y$H9[9/T'-ACI ,%Y:_7+JK/"($I.$TVDJ(:0Y$^7WGF.IE38UR0"F2N
M,.19\V\VE6N!+0H=4HTWZ/EYDFX1$1$1$1&1?P52;/ YLX%4L)I(=X_E&#$R
MC0$FQ,*?E35"Q#![*1$XJ^T$KAE$R4CKCDQZLCLF6D48^?CXP$%CHEVDR4?U
M&9G87:!"Q(ZT@32IM&HMB$0T@R/F.5:9HF>C0P=N,N@21. ,TG\DCU43P2P'
M\XP^>XN(B(B(B(C(/PH&#ZQSJXD"X2-(,A*P-L_<J:ECG(0@G(V[1/V,JP@F
M!)@B8(G!!XZ.:A%'1ZFH63Q8W6.S4;6+5"0R?,=V[2+KK&E'3MJ95-V#4]B-
M\J'LCME 3G8=(3=W)5!G520RI ;A5:O4DQ%0MUP@$1$1$1$1D;\<5MRLCHF3
M4'T-8OV;*4I1,]B.V</&B IXILP#01!^DV+(%-4(!/&A6GH@8F#.T<L15;N(
M#[UV@;/&FG:!^$"R%0)R;I$:FIRGPY.%C=E+LV'Y;Z9WP3IE=PP)0H'T$VE<
M2$1$1$1$1$3^:6(MO"MQ'5.=8(V< D+:3E" H)$G31%(?EI]1M86]1D:%-$
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M8>5[TEH@S170*WC7?]+, &L$+"@>'Q\Q%:">J##C9O2!/5F5Q_H]:B ,Q5K
MS]00&GVCRB"]RI%20.Z"G\@DYVD5*^J_: @<8F,,D)XF2B<!4?D<=6)Z@4=,
M=D5U+6F"<HB(B(B(B(C\)% AFMB8/9A/U/?[* _S'8E6$:1Q!:XBL6]6V @7
MB .Q5(]U>K6=R#7[W3&-:1#%J#]M%;!_2)L-=AQ*'[G>C]VC/11K(EVP!1,1
M8FO4IA('([[*0!DGNW$-.C- "\JH'8T[#_U):SD6&48N/JZ(B(B(B(C(/\')
M2(^Q7D[CAPSCR:HY@TEN@9B66&X0^P)S#HP*AI85E&%%__KZBN-&+.W76IOV
M(;O/#B -=UWRTP27E@#=@ PI4;CF)TVJPTLT];)@%T0=V14?G'HL%)*U?>DW
M'49$Y'O G2V9?]L\J*_9=ZTQ1%'FH1V/RGA6K^U8Z[^@S'SW+2W?>&KQ/,=1
MD0A.Y WO=^'<WS> PC\Y%KW'\#IIV\8+=-85O(;)*=^D?E*MU0MQ<0+T.?UM
M?/(4ZBY<N+5=FJLV9/*K6:MG/F.L-]47=9J(B/QO:;*--+P?_!<P R 79Q3.
M))YGO?1G21X#&4H()@2LV;%>B)9DP@XRA&Z,(PK5I2))@XIFXQ:I 66@,?GH
M0<^Y>)Z6 4NY!!DAI&EPSF<^#K O44\O.ZZ(R+G$,QG[-&S;FN=>^@GR$&N&
M%>(F\5"-AW\O#M3\4W-)-@IC@=;KTICDQ;&:)SPIJRBP-FQE,JEH2;\[8T%O
M$;<<TT+!6N1DC/<FH96S?]9.*IJ7G?9^L)F\VT:S?HQ*L&SLCT7SAH-C/>*P
M$RB3%H]G#=_G$J=0^[R!D.!;1( AT?(:IKN_$ 2_NOXLHGG#VY@1?VTO9F+#
M"]?/0WCS,K\]HB=/3F#BE.O5'RH2L;'O-W[.*A@B(G(K<+48SJ9B8$U+AK1#
MB)&(B1^?-R;7P+H@QK4J2M1$I522 2CB0XRGVS-W((,T435V(\&!B1R:QMKT
M@XGQ;F2\D7,&G%_J9/(",M)%2A"\ZZ%S^@@>L26G :@<7SH_%!%IR$&AC[33
M!$;NE_]W1W>\X6,S-=OYDY]U:_-8[A_UC;22>:C[M7R20U(ORZ2!W&Z48ZL^
MJ]=&EDQN-5R6]D_[H12?Y:-_^E->HSG?]%*LQZI;UK3]>L1H\- :A$MS]_4&
M@4V/#3E70LFA?WXAKA]YHWN1 2=7H;]/^N8UN_0J!)K;O)=.YEB/;YMXZ?WM
MP80D"^!O6X.B7QP03$1$I %#B#IX\88E1I\<*#.,)*X?%&,2NR5!)Q,_Y(LZ
MCXJ!-1..Y#A. $]>+FRQ*Z#]F1"D>HXTY)":+PCZ22QOCCBO9CI1I8R;B ;-
M-(^(%J]'\%AIWLO<'>U>T':^VBY71*22JZ%^?=HL)YO52B[>AV8/J1M,RC3U
M\-C_.,)Z,-_\-C5\FW:Q.ZS]^S)KVD5=&")08\@'&>.H&738*X>\#!F]._I:
M)@28ZIMZ=S 1P?X?:IBIH7S1+.%[^>*/:!=QQ-="AOC.T]P^6-?.28O*O!!I
M\+ ER=J<ZHA*^_,>SNO8WX0Y'ZO7[OV0>JS65G?)7VMF;1LRGTCTPEIS;Z2!
M[NXP<4JG$FZJNZ/EJOZM(B)R$Q#,<T*5OB&Q/:=;#(@Q]-3)0"H2)X>DG&CU
M0V2^C,N!;SG:[FY) (K"0!P,IE(YN]AU;R72]H.)61XE:V,(KJE4AVE*MAN$
M3,AWE)F]I7^92(\Q?;T[IFUE]]TVU4A$Y(:D"+#[K _$]DP;/5Q&Y;?]([TW
MI9BDG,Z2:V]R68,WC^COU"YVH[7_FG:!H\W\C**JH5!0_\V%[61EG8/.VHJ^
M+D+[%P>]I4<S!OT1[6(H<U418&,JKMHY:](9%^(FI\;]T _B:<#0&/!42YO^
M/JEW4?-ZB/G,9+8P%R[R95#:4?3:1?YP^I]ME>:NUWQ$1$2@1NQDH&&4R>D6
M0U+&OLC!D0)71EW S[=."9A!(3),QKL4'\B1BD4ELS+L*^I<*RT_B2+%J[$J
M7S0J2A4Q>JZTNZB=R0L7)@:<<M-LY@F<%)]Y$^=;#!'Y?H9K_%P]U2#&N<:)
M#[DB[M=*==^4)H;KQZJ<Q/.0R -]_,!>6_X>[:(^NIN@&4/MHI[.E2N[D]I%
M%8@F*]E<._?Z0V[O7S<TA_CCVL5R-!.ES,EX"[5SOFV)'2WO>VE-NT@-82T\
M135$R8WYR\(< KN4YP-]3)AA"[-/4M?JM8O:MDDE-WGI(R(BLARG58SO"/7-
M<AXSU+N2:@1RZG7]6K[9PBI^$O6"MI$3A%EBAN-@GEF=KW='HPLB7<1747/\
MRX&8:.7<DB%X:'&17'F^.<V@GYG8IS4++BVU,4L)A<&4S%<8(O)'R%5AU0%J
MV.%<K51SOG[EGO"XXU&?JZVUJ N-D0/NC8C5\:@<K@>7SRH!UG<]$W/]+=H%
MHT\-8E#K&6H7^3)]HJALY*1V,;QJ0ZK_9MW>3 9R8$WUX*_2+I9BHG,RJ'@5
M.O[@2X%J]]+<A"?/)2<\P[NN9H&OOYUAA$_(7R+SJVI8M693U/NQ5E'(%RXB
M(G(K&)52,[\_\''(PY7+9SPKZRY\8/9U<T7]XY"&E3&Q'^\8X@E<&0,K?JFX
M>#!')1AX':;OCN'',< @]VN<5_J)U-BD#;VM[#7SS,9;9#DZXS1S$B)[][,I
M^L3W%R+RIVA6RKFT3Z$UU[G8E54SLZ:J?![R %SS24GJ^FX-'NQUKUKM22ZV
MN^!==B-?T)*A=L&3?[<2VG28T7+C%>E)]X&3@_7:,KEJ2C4V8[UV?Y5V,;<'
MJ.0=.PQ$^0T0VZHJ0DUXD[Q[U]Z;I&E3<WTSXL3N&/*KL2D=&G+D[9J_A8EV
M46U6HSS64+QM:6*GFW!$1$1N!6]2:@Z+'.#ZR&/IE,&@Q@SAYODZ"5QV-\HZ
MQQ&)RD56^HQB0>/[\!&\=""*U]TQ;U>4H09>'M4@WC6Z>/9#5G5QD,SZ\JLQ
MJ.Y]D,GKUTQW-;H0D3]+M6Q?BOZ03ZKJH)&%AV-$DR=ZZ7P5^UTRB'&O*J^M
MR!KMXFY$?GN-=K&4YW:M[5SM L?&AF%VCRQ/5=^C72R?8RPP3*M=7  W<Y-S
MI _H>K%VL1QG=[CE9H3/-)[I#Y>A1*OMTT2[6$I7U]]7\Y/\AKM"1$3^/S0Y
M1&+PPBQA&&"S'T;9<MLT6(R&Z S-5VR, C2 %Q9I?<$DJ@\<049XY@G88&"V
MD<GN,<;8G0)GD\O(J1VS7.8D=:Z+7VJ69T*2Z@V15)T B,@?I%E,96SDWEB=
MU-5\[M^ZIJS!ZUJH>1,F8PI+,'(SX<*/@IT/ZJ%[(PW^&-&_:ZZ[;]<NEDZ^
M(*=V?T83GQ%D]H1])ZKU%I^1;-+$YS&7J'WG][X\5;[@6O]5VL7V*)%G!<>X
M%43H:O*(#6.!;HE5,HG6PK?]QJ&V4W^2C:EMU2Z&IAJ-:1/O6?+G;+P+$1&Y
M+4Q^MDPYL$*L<QC>Z?26 ]=0@U?WVTD,1]SO=+G-();-G"K%BH"W5WP(F/%R
M[M7;>L+%$DWO],V$I&DP\4;H6R:W1KH0D;^*NM)G;5)70/DB.ZTCAD84C75<
MSS#JQ60%E-8%NRZIZ#?$ZFQ2/#0OTX?#1_9 (XF3)CNAS#7:11..\F24@UXD
M'\8A:4;,E&+^N':Q4:N!VCEKP3"SVIN(&TUN'52+2<TUW\?P_E^+-3II<)4I
MLE6I/R"X5?)"\V*KJ0U!@W"@ ?Y3O>OQ>=TD(B*R#F/]QO&%MT(8/U >L^$8
MW6XX/#$_:49)Q H&1R8G%& NS<!-PW)60%/Q$$GM(L9B9MWQ@7TS0FEU'NFY
M[ 3KQ)@MV4(,1?IH&P@L^;:"R8-O+D3DCU.3-O8KQ(\N[6G_OCAKX.'<L&;0
M3LUKR[&UH(O?KUTLG7P!DQRI9'/H&T;TIWY96CDW1^K0HC*=!8;U#+6+I9,O
M=NN9<*/^6TT/YMK%1TG-V<]),-=I=JG!O=<B6&*9.<S B]GG!>TG&?K)8;W^
MW-:\:/N;D!\+MIU]G;W=1;6ZF1.-:9HW%,3J3^"&+[9$1$0 @XKY$!.#48:%
M3^F@!KX8FBQ>!K.=QG"1%3V36SQ!:N@P=MD=XWS23J8'[,4'A(LX4Z9\=\<,
M?7F@9N*=\]YFR-[(T X3:^I4@7AAT<P<\N57YE6YKD=%1&Y#];#K%W0U<]-N
M%%XXE]O#A55^V]C=4>W=(>E5?*XQ+:O5>C,,_1'M8AG)%[T44Z5RQB:B'>(+
M4QUAUG*O+-NTBUJ,TR17)H9_O!3(K_H#K6D7R^?(TKN1=D$$JKM#MJ^;R._5
M'Z0:J,3I--E>F@[GBF#G,.D<+@2=0YUD/>L[&9V$4]LX\ZF13O&J&-)(*+5Y
MT1ANDN;"-2]Z<A<L-O/'P@N:E =SRI?SJR&U<YI?)9>#.57^'NN%T.A"1$2^
M E3W831XR#$W1U4&QPPS/K24N'D+&0UQ&R&]*:UB1H%O2#-)PQ476T<F6K$7
M*5]S<*^B38:#R\D80_8%+AMIO-KX>V8G(P<QJ<;&$EDC/4>84>@N*B)_#_6%
M>R^KUO5^'R,HG3O6!HNA]T=OSH&"W<3M1 IN&O/5VL5:S?5$^J7T\ME(($^J
MCW:( K\V-.<[]/D(U4@EPV.MR0L3WY^E"]W9Q_?.^F^BP-<>N_M,/;O^6'4Y
MWYM/G.P<1(\:/J(*$1O]2=<RFC4T7;W6O/RW2:]#^<9QB=]+W:NQE\" I*?Z
MX" 3Y2Y-TIG^$'W>'Q$1D5N123>:[>G4$.-77>-CY%!%>*:(7R>S$T=T=YC0
MYDL'7DZA8^R._I@9Z"RM+/B,,H!\P9QJTEH4#,R8&WUC"SGB3^;,0!S.'.7K
MW(!&WC84JHC(-?!$94$TU"[RVV9!G:^J)[9D\1A$T;T[Q%;*YV&^:^[SC+!H
M:L(=YUZ\;>^=4!(T< [7>QGD,K9_C&-1L*7FX=@*))2L*D>>4;[.'NX(V9];
M1EZ"5/?'JDZ@#7DU^[QC?3]$R8G[S/4AFY"P[M9A)!T.N*FQK)E)Y(7HU^-Q
M:ZUE;-^=$^4C;^PY0YDH0XMOOW#]+KE7?+5QGL9ITK#F-#%-Z7^2\X:)B(C<
MA)P5Y/#$2A]%HK$7K18%.3RE:<3765]D%E>&R!@<B;>9=B/,>Q$<T#&8_F&
M05"LFOET,IOBC0.?S_5I70Z1-VAD3FNCDMZY.\66W3$E"LD'EZ,']PT]<41$
MK@<9(>G7^_7;_BL,XR<Y'VOFD6:YQ&,9KPKD:-).K2WP:VV3T(59IJD'57RX
M.Y9R-'*MYNRH29GE&#:A/Z,M3WXJ'UZ(C<=JW#,;:@>N%>-R4&:XQL=/X7J[
MB^SS(9D)=&WW*#,/,7%NYT1ARFQL/R:CDU/@:JZ%W< QEJSN\]O^XC/JJ3?
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M6:R51+CX&18I(B(B(B(B(M_/T]-3K*Q/AK[,;*3Q82)*5&^+6-W'@OV?".^
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M1$1$1$3.(I;8^_W^5\?OW[]CS5Z7WJ^OKWP5V^N.]_?WM5A\?GAXB.WQ+?I
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M96%M"GB<[<&!     ,,@?^K=X 15 0
M
M
M
M
M
M
M
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/968*,S4X.3(*)25%3T8*

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            April 22, 2025

Brian Hahn
Principal Executive and Financial Officer
GlycoMimetics, Inc.
P.O. Box 65
Monrovia, MD 21770

       Re: GlycoMimetics, Inc.
           Amendment No. 1 to Registration Statement on Form S-4
           Filed April 4, 2025
           File No. 333-285035
Dear Brian Hahn:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our March 17,
2025 letter.

Amendment No. 1 to Registration Statement on Form S-4
Cover Page

1.     We note your revisions in response to prior comment 1. Please tell us
how your
       disclosure in the third paragraph on the second page of your cover page
regarding the
       number of securities you are offering ties to the fee table (where it
appears you are
       registering the offering of fewer shares of common stock than disclosed)
or revise
       your disclosure or fee table as appropriate.
Questions and Answers about the Merger
What are the U.S. federal income tax considerations of the Cayman..., page xi

2.     We note your statement that you intend that the Cayman Redomestication
qualify as a
       "reorganization" within the meaning of Section 368(a) of the Code and
that, assuming
 April 22, 2025
Page 2

       it so qualifies, a U.S. Holder of Combined Company stock will not
recognize gain or
       loss upon the Cayman Redomestication. Please file an appropriate tax
opinion
       regarding this intended tax treatment as an exhibit to the registration
statement. Refer
       to Item 601(b)(8) of Regulation S-K and Section III of Staff Legal
Bulletin No. 19
       (CF), available on our website.
Prospectus Summary
The Companies
Crescent, page 1

3.     We note your disclosure that Crescent intends to submit an
Investigational New Drug
       application to the FDA for CR-001 in the fourth quarter of 2025. We also
note from
       the disclosure on page 280 that it appears that Crescent intends the
Phase 1 trial to be
       open to "solid tumor all-comers." Please specify here, and in other
locations where
       appropriate, what indication(s) Crescent anticipates its IND will
specify. In this
       regard, we note your disclosure that ivonescimab demonstrated
significantly improved
       progression-free survival compared to pembrolizumab in the HARMONi-2
trial where
       the indication was for the treatment of na  ve advanced and metastatic
NSCLC. If
       Crescent's anticipated Phase 1 trial will study a broader indication
than the
       HARMONi-2 trial, please clarify in an appropriate location any risks
from pursuing a
       broader indication.
4.     Please continue revising your disclosure in response to prior comment 8
to further
       clarify the current state of Crescent's business. Specifically, please
clarify what you
       mean on pages 2, 273 and 322 when you state that Crescent is "advancing"
its
       expected second and third programs, CR-002 AND CR-003. In this regard,
we note
       your disclosure that Crescent has not exercised the option for CR-002
and has not
       entered into an option agreement for CR-003.
5.     We note your response to prior comment 9. If true, please further revise
your
       disclosure to clarify that Crescent's intent to seek regulatory
approvals for CR-001 to
       treat multiple solid tumor indications is subject to successful
completion of clinical
       trials, which have not yet commenced, and that it will be several years
before Crescent
       will be able to commercialize CR-001, assuming it is able to
successfully complete
       clinical trials and obtain the requisite regulatory approvals.
6.     We note your response to prior comment 10, and we reissue the comment in
part.
       Briefly describe the influence, if any, that Fairmount and Paragon may
have over any
       decision by Crescent to exercise the options and in negotiating the
terms of the
       respective licensing agreements. In this regard, in addition to the
relationship between
       Crescent, Paragon, Fairmount and Parascent, we note the affiliation of
two of your
       directors with Fairmount and the rights of preferred stockholders to
elect directors
       with superior voting rights.
Risk Factors
Risks Related to the Combined Company, page 95

7.     To the extent appropriate, please revise your risk factors in this
section to distinguish
       between risks related to the Combined Company before and after the
Cayman
       Redomestication. For example only, we note some of these risk factors
address
 April 22, 2025
Page 3

       provisions of Delaware law and the Combined Company's certificate of
incorporation
       and bylaws under Delaware law without acknowledging that such law and
documents
       will no longer govern the Combined Company following the Cayman
       Redomestication.
The Merger
Crescent Restricted Stock Units, page 144

8.     We note your disclosure that each restricted stock unit representing the
right to
       receive shares of Crescent common stock will be converted into
restricted stock units
       representing the right to receive shares of GlycoMimetics common stock.
Please
       revise your disclosures on the prospectus cover page, in the
"Explanatory Note" and
       elsewhere (e.g., on pages iii, iv and vi) as appropriate to reflect this
exchange or
       otherwise advise.
GlycoMimetics Directors, Officers and Corporate Governance, page 174

9.     Please clarify in this section that Brian Hahn ceased employment with
you in
       February 2025 and now serves as your Principal Executive and Financial
Officer in
       his capacity as a consultant. In this regard, we note your disclosure on
page 184
       regarding these arrangements.
GlycoMimetics Executive Compensation
Executive Officer Separation and Consulting Agreements, page 184

10.    We note your disclosure regarding separation and consulting agreements
you entered
       into with each of Harout Semerjian and Brian Hahn. Please file these
agreements as
       exhibits to the registration statement. Refer to Item 601(b)(10)(iii)(A)
of Regulation
       S-K.
Crescent Executive Compensation, page 192

11.    Please identify Jonathan Violin as one of Crescent's named executive
officers for the
       2024 fiscal year and revise your officer and director compensation
disclosures
       accordingly. Refer to Item 402(m)(2)(i) of Regulation S-K, which
specifies that all
       individuals serving as the principal executive officer during the last
completed year
       are named executive officers.
Crescent's Business, page 272

12.    Please continue revising your disclosure in this section in response to
prior comment
       21 to remove statements that may imply that a product candidate is safe
or effective as
       such determinations are solely within the authority of the FDA and
corresponding
       regulatory authorities. For example only, we note your statement on page
277 that
       "[t]he design of ivonescimab drives its effectiveness" as well as your
reference to
       "increased effectiveness" on the same page.
13.    Refer to the WuXi Biologics MSA and Charles River MSA agreements
described on
       pages 285-287. For each of these agreements, please revise to disclose
the amounts
       and dates of any consideration or fees exchanged related to these
agreements, and
       disclose the extent to which any work orders have commenced pursuant to
these
       agreements.
 April 22, 2025
Page 4

The design of CR-001, page 278

14.    We note your revised disclosure in response to prior comment 26 that,
pursuant to the
       Paragon Option Agreements, Crescent holds options to acquire the
intellectual
       property rights to the composition of matter claims filed by Paragon for
the CR-001
       sequence. If true, please revise your disclosure to clarify that
Crescent has exercised
       its option for these intellectual property rights and expects to enter
into a license
       agreement with Paragon for the same prior to effectiveness of the
registration
       statement. Alternatively, clarify whether such intellectual property is
subject to
       options other than the option already exercised by Crescent.
In vitro activity, page 278

15.    We note your response to prior comment 27. Please further revise your
disclosure to
       provide the p-value for the data presented in the second graph in this
section or
       otherwise advise.
Clinical potential for CR-001, page 279

16.    We note your response to prior comment 28. Specifically, we note that
you now refer
       to the potential for CR-001 to receive "first-in-class" approval in
select indications.
       Given Crescent's early stage of development and the length of the drug
development
       process, such characterization appears to be premature. Accordingly,
please remove
       the statement or otherwise advise.
Planned clinical development of CR-001, page 279

17.    We note your response to prior comment 29. Please further revise your
disclosure to
       disclose the "other jurisdictions" where Crescent intends to conduct its
proposed
       Phase 1 clinical trial for CR-001.
Management Following the Merger, page 342

18.    Although we note your revisions in response to prior comment 35, given
that each
       Preferred Director shall be entitled to three votes on each matter
presented to the
       board of directors, please disclose whether those provisions will
effectively give the
       Preferred Directors control over decisions to be made by the board
following the
       merger and include risk factor disclosure as appropriate. In this
regard, we note that it
       appears from your current disclosure that each of the four non-Preferred
Directors will
       have one vote and that each of the two Preferred Directors will have
three votes, such
       that of the total of 10 votes, the Preferred Directors would have 6
votes and may have
       effective control over decisions to be made by the board following the
merger.
Executive Officers and Directors
Director Independence, page 346

19.    We note your disclosure that you expect that the Combined Company's
board of
       directors will determine that Peter Harwin is an independent director
under Nasdaq
       listing rules. We further note your disclosure on page 344 that Peter
Harwin co-
       founded and is a Managing Member at Fairmount. With a view toward
disclosure,
       please tell us whether, and if so, how, you expect this relationship to
impact the
 April 22, 2025
Page 5

       independence determination with respect to Peter Harwin, particularly
considering
       Nasdaq Listing Rule 5605(a)(2)(D). In this regard, we note the related
party
       disclosures regarding both Fairmount and Paragon. If Mr. Harwin would
not be
       considered an independent director, given that each Preferred Director,
including Mr.
       Harwin, will be entitled to three votes on each matter presented to the
board of
       directors, please tell us whether the Combined Company would have a
majority
       independent board.
General

20.    It appears that you intend to change the jurisdiction of incorporation
of the Combined
       Company from Delaware to the Cayman Islands after effectiveness. Please
tell us
       whether the Cayman Islands entity intends to file a post-effective
amendment to the
       Form S-4 expressly adopting it as its own registration statement for all
purposes under
       the Securities Act and the Securities Exchange Act. Refer to Securities
Act Rule 414.
       Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494
if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jessica Dickerson at 202-551-8013 or Tim Buchmiller at 202-551-3635
with any
other questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Kostian Ciko, Esq.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
